Order or notice
Ayush Suraksha portal: how to report a misleading ayurvedic advertisement
Last checked 10 October 2026
The Ayush Suraksha portal, launched on 30 May 2025, takes public reports of misleading AYUSH advertisements and adverse reactions; it reported 35 misleading ads and 181 complaints resolved by Dec 2025, but publishes no list of ads, products or actions.
- Classification
- Regulatory notice or advisory
- Decided by
- Ministry of AYUSH: PvPI-ASU&H, National Pharmacovigilance Coordination Centre at AIIA
- Reference
- PIB release of 2 Dec 2025; PIB release of 3 Dec 2024; Lok Sabha reply reported by Outlook (2026)
- Latest action
- 2 December 2025
- Last checked
- 10 October 2026
Photo: An Ayurvedic Pharmacy, Rishikesh (1).jpg by Ken Wieland from Philadelphia, USA (CC BY-SA 2.0). All photo credits.
Ayush Suraksha: pharmacovigilance and misleading advertisement reporting portal (PvPI-ASU&H)
Scope. A record here does not by itself mean a product or company is unsafe or banned today. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Below: Blacklisted's explanationWe organise and explain what the document says. The document above is the authority.
Key facts
- Launched
- 30 May 2025
- Network
- PvPI-ASU: 1 national centre, 5 intermediary and 99 peripheral centres (PIB, 3 Dec 2024); complaints are forwarded to State Licensing Authorities
- PIB, 2 Dec 2025
- 35 misleading advertisements reported by the public; 181 complaints resolved (Odisha 145, Kerala 22, Tripura 10, Puducherry 4)
- Lok Sabha reply (reported by Outlook)
- 10,269 misleading-ad complaints and 216 adverse drug reactions within a year; Maharashtra 1,112 (all disposed), Delhi 369 (322 acted on), Kerala 108
- Not published
- No public list of ads, products or actions
The Ayush Suraksha portal is run by PvPI-ASU&H, with its national centre at the All India Institute of Ayurveda. It was launched on 30 May 2025 and has forms to report adverse drug reactions and misleading advertisements for AYUSH products. It does not publish a list of advertisements, products or actions.
The Press Information Bureau reported on 2 Dec 2025 that the public had reported 35 misleading advertisements and that 181 complaints had been resolved (Odisha 145, Kerala 22, Tripura 10, Puducherry 4). A Lok Sabha reply reported by Outlook gave a much larger count: 10,269 misleading-ad complaints and 216 adverse reactions within a year, including Maharashtra 1,112 (all disposed), Delhi 369 (322 acted on) and Kerala 108. The sources describe the counts differently and do not reconcile them.
According to the PIB release of 3 Dec 2024, the PvPI-ASU network has one national centre, five intermediary centres and 99 peripheral centres, and complaints are forwarded to State Licensing Authorities. The published figures name no product.
What this means for you
How to report
Use the misleading advertisement form on the Ayush Suraksha portal. Keep the advertisement, the date and the product name. Complaints are forwarded to the State Licensing Authority.
Read the numbers carefully
The PIB figure (35 advertisements reported) and the Lok Sabha figure (10,269 complaints) describe different counts reported at different times. The sources do not reconcile them and neither do we.
This is a record of official orders, not medical advice. Do not stop a prescribed medicine without asking your doctor or pharmacist.
Common questions
Can I see which advertisements were acted on?
No. The portal has reporting forms only, with no public list of advertisements, products or actions.
Official sources and primary records
- Ayush Suraksha: pharmacovigilance and misleading advertisement reporting portal (PvPI-ASU&H)RegulatorPvPI-ASU&H, NPvCC at AIIA
- Ayush Suraksha portal: misleading advertisements reported and complaints resolvedPIBPress Information Bureau · 2 December 2025
- PvPI-ASU structure: national, intermediary and peripheral centresPIBPress Information Bureau · 3 December 2024
- News